Background-Inhibition of L-type Ca 2ϩ current contributes to negative inotropy of ␤ 3 adrenergic receptor (␤ 3 AR) activation, but effects on other determinants of excitation-contraction coupling are not known. Of these, the Na ϩ -K ϩ pump is of particular interest because of adverse effects attributed to high cardiac myocyte Na ϩ levels and upregulation of the ␤ 3 AR in heart failure. Methods and Results-We voltage clamped rabbit ventricular myocytes and identified electrogenic Na ϩ -K ϩ pump current (I p ) as the shift in holding current induced by ouabain. The synthetic ␤ 3 AR agonists BRL37344 and CL316,243 and the natural agonist norepinephrine increased I p . Pump stimulation was insensitive to the ␤ 1 /␤ 2 AR antagonist nadolol and the protein kinase A inhibitor H-89 but sensitive to the ␤ 3 AR antagonist L-748,337. Blockade of nitric oxide synthase abolished pump stimulation and an increase in fluorescence of myocytes loaded with a nitric oxide-sensitive dye. Exposure of myocytes to ␤ 3 AR agonists decreased ␤ 1 Na ϩ -K ϩ pump subunit glutathionylation, an oxidative modification that causes pump inhibition. The in vivo relevance of this was indicated by an increase in myocardial ␤ 1 pump subunit glutathionylation with elimination of ␤ 3 AR-mediated signaling in ␤ 3 AR Ϫ/Ϫ mice. The in vivo effect of BRL37344 on contractility of the nonfailing and failing heart in sheep was consistent with a beneficial effect of Na ϩ -K ϩ pump stimulation in heart failure. Conclusions-The ␤ 3 AR mediates decreased ␤ 1 subunit glutathionylation and Na ϩ -K ϩ pump stimulation in the heart. Upregulation of the receptor in heart failure may be a beneficial mechanism that facilitates the export of excess Na ϩ . (Circulation. 2010;122:2699-2708.)
Key Words: heart failure Ⅲ molecular biology Ⅲ myocardium Ⅲ nitric oxide synthase Ⅲ receptors, adrenergic T he ␤ 3 adrenergic receptor (␤ 3 AR) differs from ␤ 1 /␤ 2 ARs in its molecular structure, genetic coding, 1,2 and affinities for adrenergic ligands. 3 Cellular responses to receptor activation also differ. In cardiac tissue, ␤ 3 AR activation decreases contractility, contrasting with the increase mediated by the ␤ 1 AR. 4 Consistent with this, ␤ 3 AR activation is associated with a decrease in the amplitude of the cytosolic Ca 2ϩ transient that initiates contraction. [5] [6] [7] Inhibition of sarcolemmal L-type Ca 2ϩ current 5, 7 that triggers release of sarcoplasmic reticulum Ca 2ϩ is likely to contribute to this. However, effects of ␤ 3 AR activation on other proteins that are important for excitation-contraction coupling remain to be determined. 7 The membrane Na ϩ -K ϩ pump is of particular interest because it maintains the transmembrane electrochemical gradient for Na ϩ that provides the electrochemical energy for the Na ϩ -Ca 2ϩ exchanger, quantitatively the most important determinant of total cell Ca 2ϩ and hence sarcoplasmic reticulum Ca 2ϩ that is triggered for release during systole. A modest increase in the intracellular Na ϩ concentration, and hence cell Ca 2ϩ , increases contractility. However, with larger increases in the intracellular Na ϩ concentration, Ca 2ϩ -induced Ca 2ϩ release from the sarcoplasmic reticulum during diastole may reduce stored Ca 2ϩ and cause contractile dysfunction. This scheme may explain the contribution of raised intracellular Na ϩ levels to the pathophysiology of heart failure in humans 8 and in animal models. 9 supports the widely held view that receptor upregulation is harmful with disease progression. 2, 6, [11] [12] [13] [14] It has been proposed that blockade of ␤ 3 AR activation in heart failure might be beneficial. 6, [15] [16] [17] Because the Na ϩ -K ϩ pump effectively is the only export route for the excess intracellular Na ϩ , the therapeutic success of such an approach might be critically dependent on the effect of ␤ 3 AR activation on pump activity. We examined whether ␤ 3 AR activation regulates the Na ϩ -K ϩ pump in ventricular myocytes and alters glutathionylation of the ␤ 1 subunit of the pump, an oxidative modification that is causally related to pump inhibition. 18 We also examined ␤ 1 pump subunit glutathionylation in the myocardium of ␤ 3 AR Ϫ/Ϫ mice and the effect of a ␤ 3 AR agonist on in vivo cardiac contractility in a large-animal model before and after induction of stable severe heart failure.
Methods

Measurement of Na
Electrogenic Na ϩ -K ϩ pump current (I p ) was measured in freshly isolated voltage-clamped rabbit ventricular myocytes. Solutions and voltage clamp protocol were designed to minimize nonpump membrane currents. Patch pipette solutions perfusing the intracellular compartment included 10 mmol/L Na ϩ , a concentration near physiological intracellular levels. While we established the whole-cell configuration, myocytes were superfused with solution that included Na ϩ and Ca 2ϩ . Two to 3 minutes later, we switched to a superfusate that was nominally Ca 2ϩ free and had 2 mmol/L BaCl 2 and 0.2 mmol/L CdCl 2 added. When indicated, the solution was Na ϩ free to eliminate transmembrane Na ϩ influx, which might cause an increase in the intracellular Na ϩ concentration and secondary pump stimulation. I p was identified at a holding potential of Ϫ40 mV as the difference between holding current before and after Na ϩ -K ϩ pump blockade with 100 mol/L ouabain.
Imaging of Intracellular Nitric Oxide by Diaminofluorescein-2 Diacetate
To detect nitric oxide production, we loaded myocytes with the nitric oxide (NO) -sensitive dye diaminofluorescein-2 diacetate (DAF-2DA). Myocytes representative of each experimental condition were selected randomly for measurement of fluorescent intensity with a laser-scanning confocal microscope. The average of each experiment was normalized against its control.
Immunodetection of S-Glutathionylated Proteins and Protein Coimmunoprecipitation in Rabbit Ventricular Myocytes
To detect S-glutathionylation of the ␤ 1 Na ϩ -K ϩ pump subunit, aliquots of myocytes were loaded with biotinylated glutathione (GSH). After lysis, glutathionylated protein was precipitated with streptavidin-Sepharose beads, 18 separated by gel electrophoresis, transferred to a membrane, and probed with antibodies to the ␤ 1 subunit of the Na ϩ -K ϩ pump. Glutathionylation was also detected with an antibody against glutathionylated protein (anti-GSH antibody). 18 Standard techniques were used for immunodetection of coimmunoprecipitation of ␣ 1 and ␤ 1 pump subunits in rabbit myocytes and for detection of the ␤ 3 AR in myocardium from mice and sheep.
Heart Failure Model and In Vivo Studies of Cardiac Contractility
Global damage to left ventricular (LV) function was induced by repeated selective coronary microembolization in sheep at 2-week intervals until ejection fraction remained stable at Ͻ35% over at least 4 weeks, as described previously. 19 The effects of BRL37344 (BRL) on standard hemodynamic variables and LV end-systolic pressurevolume relationships (ESPVRs) of continuous LV pressure-volume loops were determined at baseline and after induction of heart failure. Because ESPVR is relatively load independent, it was chosen a priori as the primary index of cardiac contractility.
Activation and Blockade of ␤ ARs and Downstream Pathways
The ␤ 3 AR was activated with the synthetic agonists BRL (1 to 100 nmol/L) and CL316,243 (CL; 10 to 1000 nmol/L) or the natural agonist norepinephrine (10 nmol/L). Nadolol (1000 nmol/L), L-748,337 (L-7; 1000 nmol/L), and prazosin (1000 nmol/L) were used to block ␤ 1 /␤ 2 ARs, ␤ 3 AR, and ␣ ARs. Protein kinase A (PKA) was inhibited by inclusion of H-89 (500 nmol/L) in patch pipette solutions perfusing the intracellular compartment of voltageclamped myocytes or by exposing myocytes to the membrane permeable inhibitor KT5720 (200 nmol/L) in extracellular solutions. Forskolin (100 nmol/L) was used to activate adenyl cyclase. NO synthase (NOS) was inhibited by inclusion of N G -nitro-L-arginine methyl ester (L-NAME) in pipette solutions (10 mol/L) or extracellular solutions (100 to 1000 mol/L). The heat shock protein antagonist radicicol (10 mol/L) and 1H-(1,2,4)oxadiazolo [4,3-a] quinoxalin-1-one (ODQ; 10 mol/L) were included in pipettes to inhibit NOS activation or NO-activated "soluble" guanylyl cylase.
Statistical Analysis
Results are expressed as meanϮSE. Statistical comparisons were made with ANOVA after a D'Agostino-Pearson normality test had been used to examine whether the distribution of residuals deviated from normality. A posthoc Bonferroni test was used as appropriate. Relationships between dose of BRL and hemodynamic variables before and after induction of heart failure were compared with nonparametric Spearman correlation and Wilcoxon matched-pairs signed-ranks test. An expanded Methods section is available in the online-only Data Supplement.
Results
␤ 3 AR Agonists Stimulate the Na
؉ -K ؉
Pump Current
We exposed patch-clamped myocytes to a control superfusate or a superfusate containing 10 nmol/L BRL, switching to the BRL-containing superfusate after the whole-cell configuration had been established. Figure 1A shows the timing of changes in the composition of superfusates and holding currents of a control myocyte and a myocyte exposed to BRL. BRL stimulated the Na ϩ -K ϩ pump, as shown by the increase in the ouabain-induced shift in holding current, I p ( Figure 1A and 1B). To rule out a BRL-induced transmembrane Na ϩ influx and Na ϩ -K ϩ pump stimulation secondary to an increase in the intracellular Na ϩ concentration, we also measured I p in Na ϩ -free superfusates. BRL increased I p , indicating that pump stimulation was not due to enhanced Na ϩ influx ( Figure 1C) .
Exposure of myocytes to 1 or 10 nmol/L BRL increased I p , but stimulation was lost at a concentration of 100 nmol/L ( Figure 2A ). Because BRL has imperfect selectivity for the ␤ 3 AR, we blocked ␤ 1 /␤ 2 ARs with nadolol. This restored the BRL-induced pump stimulation that was observed at the lower concentrations (Figure 2A ), indicating first that ␤ 1 /␤ 2 ARs do not mediate pump stimulation and second that nonspecific activation of ␤ 1 /␤ 2 AR by BRL leads to the loss of pump stimulation at 100 nmol/L of BRL. In an independent set of experiments, we included H-89 in pipette solutions and nadolol in the superfusate. The concentration of H-89 we used abolishes the effect of forskolin-induced PKA activation to induce a decrease in I p . 20 The combined blockade of ␤ 1 /␤ 2 ARs and the downstream pathway coupled to them had no effect on the 〉RL-induced increase in I p ( Figure 2A ). The increase also persisted in the presence of the ␣ AR antagonist prazosin ( Figure 2A ).
Although BRL is regarded as the classic agonist for the rodent ␤ 3 AR, CL is more specific albeit less potent. 21 CL increased I p , and in contrast to the effect of BRL, there was no reduction in Na ϩ -K ϩ pump stimulation with an increase in CL concentration ( Figure 2B ). L-7, an antagonist for the ␤ 3 AR, 7, 22 abolished the CL-induced increase in I p ( Figure 2B ). The ␤ 3 AR has a high affinity for the naturally occurring catecholamine norepinephrine and is sometimes referred to as the "noradrenergic" receptor. 3 Norepinephrine increased I p , an effect that was insensitive to nadolol and H-89 ( Figure 2C ). Stable currents before and after exposure of patch-clamped myocytes to ouabain were sampled with an electronic cursor to identify I p . The superfusate contained Na ϩ throughout the experiments illustrated and 10 nmol/L BRL as indicated. C m indicates membrane capacitance (pF). B, Effect of BRL on I p measured in Na ϩ -containing superfusate. C, I p in Na ϩ -free superfusates to eliminate Na ϩ influx and hence secondary pump stimulation. Numbers of myocytes studied are indicated in parentheses within columns. *Statistical significance relative to control. Figure 1B . Pump stimulation occurred at 100 nmol/L BRL when myocytes were exposed to the ␤ 1 /␤ 2 AR antagonist nadolol with or without the protein kinase A inhibitor H-89 in patch pipette solutions. Prazosin had no effect on BRL-induced pump stimulation. B, Effect of the ␤ 3 AR agonist CL and antagonist L-7. C, Effect of norepinephrine (NE). *Statistical significance relative to control experiments.
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Because the ␤ 3 AR is coupled to activation of NOS, 23 we examined NO-sensitive fluorescence of DAF-2DA-loaded myocytes. Exposure to BRL for 10 minutes augmented fluorescence ( Figure 3A) . The augmentation was blocked by preincubation with L-NAME, consistent with coupling of the ␤ 3 AR and NOS in rabbit cardiac myocytes. In functional Na ϩ -K ϩ pump studies on voltage-clamped myocytes, we inhibited NOS or blocked its activation by including L-NAME or radicicol in patch pipette solutions. Both compounds abolished the BRL-induced increase in I p ( Figure 3B ). We included ODQ in pipette solutions to inhibit NO-activated guanylyl cyclase. ODQ abolished the norepinephrineinduced increase in I p ( Figure 3C ). Oxidant cellular signaling can inhibit the Na ϩ -K ϩ pump via reversible glutathionylation of its ␤ 1 subunit. 18 Because there is glutathionylation at baseline, we examined whether the converse applies, that ␤ 3 AR agonist-induced pump stimulation is associated with a decrease in glutathionylation. BRL and CL decreased ␤ 1 subunit glutathionylation, as detected with the biotin-GSH technique ( Figure 4A ) and with the independent GSH antibody technique ( Figure 4B ). The ␣/␤ subunit interaction is critical for Na ϩ -K ϩ pump function, 24 and glutathionylation is associated with a decrease in coimmunoprecipitation of the subunits. 18 The decrease in glutathionylation induced by ␤ 3 AR agonists was associated with the converse, ie, an increase in subunit coimmunoprecipitation ( Figure 4C ).
Consistent with the functional studies shown in Figures 2B and 3B, the decrease in ␤ 1 Na ϩ -K ϩ pump subunit glutathionylation induced by CL was blocked by preincubation of myocytes with L-NAME ( Figure 5A ) or the ␤ 3 AR antagonist L-7 ( Figure 5B) . We used the membrane-permeable compound KT5720 to examine the effect of PKA inhibition on the CL-induced decrease in ␤ 1 subunit glutathionylation. Inhibition of a forskolin-induced increase in glutathionylation 20 was used as a positive control. The PKA inhibitor had no effect on the CL-induced decrease in ␤ 1 Na ϩ -K ϩ pump subunit glutathionylation ( Figure 5C ), consistent with the functional results shown in Figure 2A .
Mice Lacking the ␤ 3 AR Have Increased Glutathionylation of the ␤ 1 Na
Ϫ/Ϫ mice have an exacerbated phenotype of pathological cardiac remodeling after transaortic constriction that is mediated by an increase in oxidative stress. 25 We therefore examined whether ␤ 3 AR signaling affects downstream glutathionylation of the ␤ 1 Na ϩ -K ϩ pump subunit in vivo. The ␤ 3 AR was detected in the myocardium from wild-type mice but not ␤ 3 AR Ϫ/Ϫ mice ( Figure 6A ). Consistent with the decrease in glutathionylation of the ␤ 1 Na ϩ -K ϩ pump subunit in isolated rabbit myocytes induced by ␤ 3 AR agonists in vitro ( Figure 4A and 4B) , there was an increase in ␤ 1 subunit glutathionylation in the myocardium of mice lacking the ␤ 3 AR ( Figure 6B ). As previously shown for rabbit myocytes, 18 glutathionylated ␤ 1 subunit was not detected in the immunoblot when myocardial lysate had been preincubated with 1 mmol/L dithiothreitol (data not shown), supportive of a mixed disulfide bond between the ␤ 1 subunit and glutathione.
Effects of BRL on Contractility of the Normal and Failing Heart
We examined the effect of BRL on cardiac contractility in sheep before and after induction of severe, stable heart failure as defined previously. 19 Expression of the ␤ 3 AR in sheep heart was ascertained by immunoblotting. Myocardium from wild-type and ␤ 3 AR Ϫ/Ϫ mouse as positive and negative controls ( Figure 7A ). After determining standard hemodynamic variables and LV ESPVR in sheep at a drug-free baseline, we gave BRL intravenously in incremental doses ranging from 0.05 to 2.5 g/kg. Each dose was given over a period of 8 minutes, and hemodynamic parameters were determined after an additional 5 minutes. When the measurements were completed, we gave a larger dose of BRL, repeating the timing of the protocol. Hemodynamic parameters are summarized in Table I in the online-only Data Supplement. Variability of the reference level for pressure measurements relative to the tip of the LV Millar catheter contributes to the coefficient of variation of pressures, and each measurement at the different dose levels in failing and nonfailing hearts was normalized to the corresponding drugfree baseline value. The normalized parameters are summarized in Table I in the online-only Data Supplement. The normalized parameter at each BRL dose in a nonfailing heart was matched with its corresponding value at the same dose after induction of heart failure for each of 4 sheep. There was a positive correlation between the rate of LV systolic pressure increase (dP/dtmax) for the failing and nonfailing heart with increasing BRL dose (Spearman correlation coefficient, 0.72; PϽ0.05). There was no correlation with dose for peak systolic pressure, stroke work, LV diastolic pressure decay (dP/dtmin), LV end-diastolic pressure, or cardiac output. A paired replicate rank test indicated that peak systolic pressure and dP/dtmin were significantly higher with BRL administration for the failing than the nonfailing heart, whereas LV end-diastolic pressure was significantly lower. There was no difference between the effects of BRL on stroke work and cardiac outputs in failing and nonfailing heart. Figure 7 shows examples of LV pressure-volume loops in nonfailing (B) and failing (C) heart. BRL induced a decrease in ESPVR in the nonfailing but an increase in the failing heart. Each ESPVR measured was normalized to the value at the drug-free baseline. There was a negative relationship between the dose of BRL and ESPVR in the nonfailing heart, consistent with a negative inotropic effect of the drug (PϽ0.05). However, there was a significant shift of the relationship between the dose of BRL and ESPVR in a positive direction after induction of heart failure (paired replicate rank test, PϽ0.05). The Spearman correlation coefficient between values ESPVR for failing and nonfailing hearts at different doses of BRL was ϷϪ0.2 ( Figure 7C ).
Discussion
In vitro exposure of rabbit ventricular myocytes to ␤ 3 AR agonists induced a decrease in glutathionylation of the ␤ 1 subunit of the Na ϩ -K ϩ pump that was functionally important, as indicated by an increase in Na ϩ -K ϩ pump current. The in vivo relevance of this finding was supported by an increase in glutathionylation of the pump subunit in the myocardium from ␤ 3 AR Ϫ/Ϫ mice. These findings are likely to be important for our understanding of ␤ 3 AR upregulation in heart failure.
There is a complicated species dependence of the structure, ligand affinity, and expression of the ␤ 3 AR. 7, 22 We used rabbit ventricular myocytes that express receptors with a high degree of functional similarity to the human receptor. 7 It is unlikely that Na ϩ -K ϩ pump stimulation was due to nonspecific activation of ␤ 1 /␤ 2 ARs because PKA, expected to be activated downstream from these receptors, mediates an increase in glutathionylation of the ␤ 1 subunit of the Na ϩ -K ϩ pump and a decrease in I p . 20 PKA inhibition had no effect on the increase in I p or decrease in ␤ 1 subunit deglutathionylation with ␤ 3 AR activation. Furthermore, activation of ␤ 1 /␤ 2 ARs caused a loss of BRL-induced pump stimulation at high concentrations, as indicated by the restoration of stimulation with exposure to nadolol, with or without H-89 ( Figure 2 ). The downstream dependence of Na ϩ -K ϩ pump stimulation and ␤ 1 subunit deglutathionylation on NOS implicated the ␤ 3 AR, and the role of the receptor is directly supported by the effects of the antagonist L-7. The colocalization of NOS3 with the ␤ 3 AR 14 and Na ϩ -K ϩ pumps 26 in a caveolar microdomain is expected to facilitate this functional interaction. ␤ AR-mediated Na ϩ -K ϩ pump stimulation in cardiac myocytes has previously been attributed to activation of ␤ 1 /␤ 2 ARs and PKA-mediated phosphorylation of phospholemman (PLM), a member of the family of single transmembrane-spanning FXYD proteins that associate with the Na ϩ -K ϩ pump and regulate its activity. 27 Isoproterenol (1 mol/L) was used to activate ␤ AR-signaling pathways. Absence of an effect in myocytes from PLM Ϫ/Ϫ hearts supported a role for PKA-mediated phosphorylation of PLM. However, isoproterenol is expected to activate the ␤ 3 and ␤ 1 /␤ 2 ARs in the concentration used, and we have now found that PLM mediates deglutathionylation of the ␤ 1 Na ϩ -K . This is dependent on the susceptibility to glutathionylation of a specific cysteine residue in PLM identified by mutagenesis.
It may provide an alternative explanation for the absence of an effect of isoproterenol on Na ϩ -K ϩ pump activity in PLM Ϫ/Ϫ myocytes. Additional factors contribute to controversies around the effects of adrenergic signaling on the cardiac myocyte Na ϩ -K ϩ pump, as discussed previously. 20 Glutathionylation is emerging as an important mechanism for the regulation of protein function. 28 Oxidative stimuli, including activation of adenylyl cyclase that is coupled to the ␤ 1 /␤ 2 ARs 20 or exposure to angiotensin II, 18, 29 can induce glutathionylation of the ␤ 1 Na ϩ -K ϩ pump subunit and cause pump inhibition in myocytes. Oxidation-induced glutathionylation of the ␤ 1 subunit expressed in Xenopus oocytes and pump inhibition is abolished by mutation of a specific cysteine, indicating a causal relationship between glutathionylation and inhibition. 18 The glutathionylation is associated with a decrease in coimmunoprecipitation of the ␣ 1 and ␤ 1 subunits, 18 the interaction of which is critical for overall Na ϩ -K ϩ pump activity. 24 Conversely, in the present study, deglutathionylation was associated with an increase in ␣ 1 /␤ 1 subunit coimmunoprecipitation and pump stimulation. These results support a central role for the glutathionylation state of the ␤ 1 subunit in determining Na ϩ -K ϩ pump activity. To the best of our knowledge, the ␤ 3 AR-mediated effect we report here is the first example of receptor-coupled reversal of an oxidative modification of a key cellular protein causing a change in function.
Deglutathionylation is catalyzed by glutaredoxin 1 (GRx1) with exclusive selectivity for the protein-glutathione "mixed" disulfide. 30 Coimmunoprecipitation of GRx1 with the ␤ 1 Na ϩ -K ϩ pump subunit and functional studies implicate GRx1 at the molecular level, 18 but at the cellular level, regulation of deglutathionylation is poorly understood. 28 Signaling mediated by NO-activated guanylyl cyclase is implicated here, but to the best of our knowledge, no posttranslational modification is reported to activate GRx1. In contrast, as its name implies, PLM can be phosphorylated in response to cellular signaling. Phosphorylation of serines 63 and 68 in the cytoplasmic terminal is firmly established, as reviewed previously. 31 Recently, phosphorylation of an amino acid in position 69 has also been reported. The amino acid can be a serine or threonine, depending on the species. Some details of the mechanism remain uncertain, but it has been established that selective phosphorylation of serine 69 is induced by cyclic guanosine monophosphate-dependent signaling. 32 PLM-dependent deglutathionylation of the ␤ 1 Na ϩ -K ϩ pump subunit (S. Biebert, PhD, C. C. Liu, PhD, G. A. Figtree, MB, BS, DPhil., A. Garcia, BSc, E. J. Hamilton, BSc, F. M. Marassi, PhD, K. J. Sweadner, PhD, F. Cornelius, PhD, K. Geering, PhD and H. H. Rasmussen, MD, DMSc, unpublished data, 2010) may somehow be facilitated by phosphorylation of serine 69, perhaps by a promotion of access of GRx1 to the ␤ 1 pump subunit. Unfortunately, our current understanding of the 3-dimensional crystal structure of the complex of ␣ and ␤ subunits with FXYD 24 does not indicate how this might occur. The cytoplasmic terminal of FXYD proteins where phosphorylation sites reside remains to be resolved, and although the location of the reactive cysteine in the ␤ 1 subunit is unlikely to be accessible to GRx1 in the E 2 conformational state that was used to determine the 3-dimensional structure of the ␣/␤/FXYD complex, 24 its location in the E 1 conformation remains unknown. Large movements of the subunits relative to each other are known to occur during the E 2 3 E 1 transition in the pump cycle. 33 A decrease in intracellular Na ϩ levels with Na ϩ -K ϩ pump stimulation enhances Ca 2ϩ export via Na ϩ -Ca 2ϩ exchange and decreases cytosolic Ca 2ϩ available for uptake into the sarcoplasmic reticulum. This should reduce the amplitude of cytosolic Ca 2ϩ transients and hence contractility, as shown in rabbit cardiac myocytes exposed to ␤ 3 AR agonists in concentrations similar to those we used. 7 However, this cannot necessarily be attributed solely to Na ϩ -K ϩ pump stimulation because Ca 2ϩ channel inhibition 7,14 is expected to have a similar effect. Heart disease introduces additional confounders with changes in the relative abundance of ␤ ARs and uncertainty about interaction with the effect that other "neurohormones" have on the Na ϩ -K ϩ pump, Na ϩ influx, and intracellular Na ϩ . 18, 34, 35 Our in vivo studies on failing and nonfailing sheep heart indicated a differential effect of BRL consistent with Na ϩ -K ϩ pump stimulation and a decrease in intracellular Na ϩ that might have a negative inotropic effect in the normal heart but not in the failing heart. 8, 35, 36 Any upregulation of the ␤ 3 AR with heart failure 10 did not accentuate a negative inotropic effect of receptor activation; there was no adverse acute effect on hemodynamic variables of BRL in our large-animal model of severe heart failure.
The view that upregulation of the ␤ 3 AR in severe heart failure is maladaptive 2,6,11-14 was well reasoned on the basis of available evidence but should now be reconsidered. Accentuation of the phenotype that results from transaortic constriction in ␤ 3 AR Ϫ/Ϫ mice suggests that upregulation of the ␤ 3 AR can be a useful compensatory mechanism. The increase in oxidative stress implicated in the phenotype 25 
CLINICAL PERSPECTIVE
The ␤ 3 adrenergic receptor differs from the ␤ 1 and ␤ 2 types in its structure, ligand affinities, and coupling to intracellular signaling pathways. Its expression in the myocardium is upregulated in heart failure, and because it mediates a negative inotropic effect in the normal heart, this upregulation has been thought to be maladaptive. This has led to the suggestion that ␤ 3 adrenergic receptor antagonists might be useful. The ␤ receptor antagonists of proven efficacy target ␤ 1 ‫گ-‬ and ␤ 2 receptors, and we have reported that the downstream cAMP-dependent pathways coupled to these receptors induce an oxidative modification on a subunit of the membrane Na ϩ -K ϩ pump that inhibits pump activity. Because raised intracellular Na ϩ levels and increased myocardial oxidative stress contribute adversely to the phenotype of contractile abnormalities and cardiac arrhythmias in heart failure, the "␤-blockers" may limit the oxidative Na ϩ -K ϩ pump inhibition and hence reduce myocyte Na ϩ overload. Here, we show that selective ␤ 3 adrenergic receptor agonists reverse the oxidative molecular modification that inhibits the cardiac Na ϩ -K ϩ pump and hence stimulate pump activity. Activation of upregulated ␤ 3 adrenergic receptors with the increase in catecholamine levels typically seen in heart failure may be a useful compensatory mechanism, consistent with a recent report of ␤ 3 adrenergic receptor knockout mice suffering an accentuated cardiac phenotype in an aortic constriction model. It may also explain the adverse outcome in a previous large human heart failure trial when raised catecholamine levels were specifically targeted in heart failure with the use of a centrally acting sympatholytic drug.
